journal
MENU ▼
Read by QxMD icon Read
search

Lancet HIV

journal
https://www.readbyqxmd.com/read/28431924/racial-disparities-in-hiv
#1
Richard Davies Burt, Sara Nelson Glick
No abstract text is available yet for this article.
April 18, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28431923/sources-of-racial-disparities-in-hiv-prevalence-in-men-who-have-sex-with-men-in-atlanta-ga-usa-a-modelling-study
#2
Steven M Goodreau, Eli S Rosenberg, Samuel M Jenness, Nicole Luisi, Sarah E Stansfield, Gregorio A Millett, Patrick S Sullivan
BACKGROUND: In the USA, men who have sex men (MSM) are at high risk for HIV, and black MSM have a substantially higher prevalence of infection than white MSM. We created a simulation model to assess the strength of existing hypotheses and data that account for these disparities. METHODS: We built a dynamic, stochastic, agent-based network model of black and white MSM aged 18-39 years in Atlanta, GA, USA, that incorporated race-specific individual and dyadic-level prevention and risk behaviours, network attributes, and care patterns...
April 18, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28416197/pre-exposure-prophylaxis-is-approved-in-scotland
#3
Rak Nandwani
No abstract text is available yet for this article.
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28416196/another-statin-option-in-hiv
#4
Philip E Tarr, Helen Kovari
No abstract text is available yet for this article.
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28416195/pitavastatin-versus-pravastatin-in-adults-with-hiv-1-infection-and-dyslipidaemia-intrepid-12-week-and-52-week-results-of-a-phase-4-multicentre-randomised-double-blind-superiority-trial
#5
Judith A Aberg, Craig A Sponseller, Douglas J Ward, Vladimir A Kryzhanovski, Stuart E Campbell, Melanie A Thompson
BACKGROUND: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia...
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28411091/comparison-of-dynamic-monitoring-strategies-based-on-cd4-cell-counts-in-virally-suppressed-hiv-positive-individuals-on-combination-antiretroviral-therapy-in-high-income-countries-a-prospective-observational-study
#6
Ellen C Caniglia, Lauren E Cain, Caroline A Sabin, James M Robins, Roger Logan, Sophie Abgrall, Michael J Mugavero, Sonia Hernández-Díaz, Laurence Meyer, Remonie Seng, Daniel R Drozd, George R Seage, Fabrice Bonnet, Francois Dabis, Richard D Moore, Peter Reiss, Ard van Sighem, William C Mathews, Julia Del Amo, Santiago Moreno, Steven G Deeks, Roberto Muga, Stephen L Boswell, Elena Ferrer, Joseph J Eron, Sonia Napravnik, Sophie Jose, Andrew Phillips, Amy C Justice, Janet P Tate, John Gill, Antonio Pacheco, Valdilea G Veloso, Heiner C Bucher, Matthias Egger, Hansjakob Furrer, Kholoud Porter, Giota Touloumi, Heidi Crane, Jose M Miro, Jonathan A Sterne, Dominique Costagliola, Michael Saag, Miguel A Hernán
BACKGROUND: Clinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive individuals. We compared dynamic monitoring strategies based on time-varying CD4 cell counts in virologically suppressed HIV-positive individuals. METHODS: In this observational study, we used data from prospective studies of HIV-positive individuals in Europe (France, Greece, the Netherlands, Spain, Switzerland, and the UK) and North and South America (Brazil, Canada, and the USA) in The HIV-CAUSAL Collaboration and The Centers for AIDS Research Network of Integrated Clinical Systems...
April 11, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28411090/less-frequent-cd4-monitoring-in-virologically-suppressed-hiv
#7
James McMahon, Suzanne M Crowe
No abstract text is available yet for this article.
April 11, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28366707/relative-effects-of-antiretroviral-therapy-and-harm-reduction-initiatives-on-hiv-incidence-in-british-columbia-canada-1996-2013-a-modelling-study
#8
Bohdan Nosyk, Xiao Zang, Jeong E Min, Emanuel Krebs, Viviane D Lima, M-J Milloy, Jean Shoveller, Rolando Barrios, P Richard Harrigan, Thomas Kerr, Evan Wood, Julio S G Montaner
BACKGROUND: Antiretroviral therapy (ART) and harm reduction services have been cited as key contributors to control of HIV epidemics; however, the specific contribution of ART has been questioned due to uncertainty of its true efficacy on HIV transmission through needle sharing. We aimed to isolate the independent effects of harm reduction services (opioid agonist treatment uptake and needle distribution volumes) and ART on HIV transmission via needle sharing in British Columbia, Canada, from 1996 to 2013...
March 30, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28262574/health-adjusted-life-expectancy-in-hiv-positive-and-hiv-negative-men-and-women-in-british-columbia-canada-a-population-based-observational-cohort-study
#9
Robert S Hogg, Oghenowede Eyawo, Alexandra B Collins, Wendy Zhang, Shahab Jabbari, Mark W Hull, Viviane Dias Lima, Tareq Ahmed, Claire E Kendall, Keri N Althoff, Amy C Justice, Rolando Barrios, Jeannie Shoveller, Julio S G Montaner
BACKGROUND: We sought to understand whether people living with HIV (PLHIV) ever on highly active antiretroviral therapy (ART) follow a pattern where morbidity is compressed into the last years of life or lessened as people age. We aimed to estimate health-adjusted life expectancy (HALE) among adults living with and without HIV, and examine dependency between causes of comorbidities. METHODS: The Comparative Outcomes and Service Utilization Trends (COAST) study is a retrospective cohort of adults (≥20 years) including all known PLHIV and a 10% random sample of the general population of British Columbia, and with longitudinal data spanning from April 1, 1996, to Dec 31, 2012...
March 2, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28262573/liver-disease-and-healthy-life-expectancy-with-hiv
#10
Hugo Perazzo, Paula M Luz
No abstract text is available yet for this article.
March 2, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28259777/switching-from-tenofovir-disoproxil-fumarate-to-tenofovir-alafenamide-coformulated-with-rilpivirine-and-emtricitabine-in-virally-suppressed-adults-with-hiv-1-infection-a-randomised-double-blind-multicentre-phase-3b-non-inferiority-study
#11
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Bernard Vandercam, Joseph de Wet, Jürgen Rockstroh, Adriano Lazzarin, Bart Rijnders, Daniel Podzamczer, Anders Thalme, Marcel Stoeckle, Danielle Porter, Hui C Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao
BACKGROUND: Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate. METHODS: In this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-1-infected adults were screened and enrolled at 119 hospitals in 11 countries in North America and Europe...
March 1, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28259776/switching-from-efavirenz-emtricitabine-and-tenofovir-disoproxil-fumarate-to-tenofovir-alafenamide-coformulated-with-rilpivirine-and-emtricitabine-in-virally-suppressed-adults-with-hiv-1-infection-a-randomised-double-blind-multicentre-phase-3b-non-inferiority
#12
Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Claudia T Martorell, Joseph de Wet, Hans-Jürgen Stellbrink, Jean-Michel Molina, Frank A Post, Ignacio Pérez Valero, Danielle Porter, YaPei Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao
BACKGROUND: Tenofovir alafenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal risks. The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safety, and tolerability of switching to this regimen compared with remaining on coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate. METHODS: In this randomised, double-blind, placebo-controlled, non-inferiority trial, HIV-1-infected adults were enrolled at 120 hospitals and outpatient clinics in eight countries in North America and Europe...
March 1, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28259775/tenofovir-prodrugs-similar-but-not-the-same
#13
Anne Bruggemans, Zeger Debyser
No abstract text is available yet for this article.
March 1, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28256422/geographical-disparities-in-hiv-prevalence-and-care-among-men-who-have-sex-with-men-in-malawi-results-from-a-multisite-cross-sectional-survey
#14
Andrea L Wirtz, Gift Trapence, Dunker Kamba, Victor Gama, Rodney Chalera, Vincent Jumbe, Rosemary Kumwenda, Marriam Mangochi, Stephane Helleringer, Chris Beyrer, Stefan Baral
BACKGROUND: Epidemiological assessment of geographical heterogeneity of HIV among men who have sex with men (MSM) is necessary to inform HIV prevention and care strategies in the more generalised HIV epidemics across sub-Saharan Africa, including Malawi. We aimed to measure the HIV prevalence, risks, and access to HIV care among MSM across multiple localities to better inform HIV programming for MSM in Malawi. METHODS: Between Aug 1, 2011, and Sept 13, 2014, we recruited MSM into cross-sectional research via respondent-driven sampling (RDS) in seven districts of Malawi...
February 27, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28256421/improving-hiv-prevention-and-care-for-african-gbmsm
#15
Susan M Graham, Gary W Harper
No abstract text is available yet for this article.
February 27, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28233661/hiv-prevention-resources-time-to-move-toward-affordability
#16
April D Kimmel, Denis Nash
No abstract text is available yet for this article.
February 20, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28233660/prep-for-key-populations-in-combination-hiv-prevention-in-narobi-a-mathematical-modelling-study
#17
Ide Cremin, Lyle McKinnon, Joshua Kimani, Peter Cherutich, Gloria Gakii, Festus Muriuki, Katharine Kripke, Robert Hecht, Michael Kiragu, Jennifer Smith, Wes Hinsley, Lawrence Gelmon, Timothy B Hallett
BACKGROUND: The HIV epidemic in the population of Nairobi as a whole is in decline, but a concentrated sub-epidemic persists in key populations. We aimed to identify an optimal portfolio of interventions to reduce HIV incidence for a given budget and to identify the circumstances in which pre-exposure prophylaxis (PrEP) could be used in Nairobi, Kenya. METHODS: A mathematical model was developed to represent HIV transmission in specific key populations (female sex workers, male sex workers, and men who have sex with men [MSM]) and among the wider population of Nairobi...
February 20, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28219619/effect-of-availability-of-hiv-self-testing-on-hiv-testing-frequency-in-gay-and-bisexual-men-at-high-risk-of-infection-forth-a-waiting-list-randomised-controlled-trial
#18
Muhammad S Jamil, Garrett Prestage, Christopher K Fairley, Andrew E Grulich, Kirsty S Smith, Marcus Chen, Martin Holt, Anna M McNulty, Benjamin R Bavinton, Damian P Conway, Handan Wand, Phillip Keen, Jack Bradley, Johann Kolstee, Colin Batrouney, Darren Russell, Matthew Law, John M Kaldor, Rebecca J Guy
BACKGROUND: Frequent testing of individuals at high risk of HIV is central to current prevention strategies. We aimed to determine if HIV self-testing would increase frequency of testing in high-risk gay and bisexual men, with a particular focus on men who delayed testing or had never been tested before. METHODS: In this randomised trial, HIV-negative high-risk gay and bisexual men who reported condomless anal intercourse or more than five male sexual partners in the past 3 months were recruited at three clinical and two community-based sites in Australia...
February 16, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28219618/hiv-self-testing-in-high-risk-populations
#19
Victoria Frye, Beryl A Koblin
No abstract text is available yet for this article.
February 16, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28219611/integrase-inhibitors-go-head-to-head
#20
Tristan Barber
No abstract text is available yet for this article.
February 14, 2017: Lancet HIV
journal
journal
49635
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"